Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers
Tóm tắt
Indacaterol is an inhaled, ultra–long-acting β2-agonist that provides 24-h bronchodilation with once-daily dosing in patients with chronic obstructive pulmonary disorder. This study evaluated the pharmacokinetics, safety, and tolerability of multiple daily inhaled doses of indacaterol 150 or 300 μg once daily in healthy Chinese volunteers. This was a single-center, randomized, double-blind, multiple-dose, parallel-group study, placebo-controlled trial including two doses of indacaterol: 150 and 300 μg. Serum indacaterol was quantified using high-performance liquid chromatography-mass spectrometry with a lower limit of quantification of 0.01 ng/mL. The pharmacokinetic parameters were analyzed using non-compartmental analysis and included C
max, T
max, and AUC0–24h on Day 1 and AUC0–24h,ss, C
max,ss, C
min,ss, C
av,ss, T
max,ss, T
1/2, T
1/2,acc, CL/F, V
z/F, and R
acc on Day 14 (after repeated once-daily doses). Safety analyses were recorded using physical examination, biochemical tests, and ECG. Indacaterol steady state was achieved after 12–14 days of daily dosing. The mean effective half-life of indacaterol (based on drug accumulation at steady state) was 33.9 and 35.8 h for 150 and 300 μg, respectively. Systemic exposure to indacaterol increased 1.27 and 1.34-fold between the 150- and 300-μg doses on Day 1 (first dose) and Day 14 (repeated dose), respectively. Indacaterol 150 and 300 μg were safe and well tolerated in these volunteers. The pharmacokinetics of multiple inhaled doses of indacaterol 150 and 300 μg (for 14 days) were consistent with moderate systemic accumulation at steady state after repeated once-daily inhalation in healthy Chinese volunteers.
Tài liệu tham khảo
Boxenbaum H, Battle M (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35:763–766
Cazzola M, Matera MG, Lotvall J (2005) Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 14:775–783
Dahl R, Chung KF, Buhl R et al (2010) Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65:473–479
EU SMPC 2 European Medicines Agency (EMA): Indacaterol (Onbrez®) full prescribing information (EU) (2010). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001114/WC500053733.pdf. Last accessed 13th December 2012
Fang X, Wang X, Bai C (2011) COPD in China: the burden and importance of proper management. Chest 139:920–929
Feldman G, Siler T, Prasad N et al (2010) Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 10:11. doi:10.1186/1471-2466-10-11.:11-10
GOLD (2013) Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011 update. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb19.pdf. Accessed on 22nd Mar 2013
Hosoe M, Woessner R, Matsushima S et al (2011) Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies. Clin Drug Investig 31:247–255
Khindri S, Sabo R, Harris S et al (2011) Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 11:31. doi:10.1186/1471-2466-11-31.:31-11
Kinoshita M, Lee SH, Hang LW et al (2012) Efficacy and safety of indacaterol 150 and 300 microg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 17:379–389
Kornmann O, Dahl R, Centanni S et al (2011) Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37:273–279
Moen MD (2010) Indacaterol: in chronic obstructive pulmonary disease. Drugs 70:2269–2280
Pavkov R, Mueller S, Fiebich K et al (2010) Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 26:2527–2533
SFDA (2005) State Food and Drug Administration, P.R.China, Guideline No. [H] GCL 1–2. Technical Guideline of Clinical Pharmacokinetics Research on Chemical Drug (in Chinese)
Zhong N, Wang C, Yao W et al (2007) Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 176:753–760